Clinical Trial Update: AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating saracatinib (AZD0530) in adults with recurrent, locally advanced, or metastatic soft tissue sarcoma has completed, with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatofibrosarcoma Protuberans
• Endometrial Stromal Sarcoma
• Fibrosarcoma
• Leiomyosarcoma
• Liposarcoma
• Rhabdomyosarcoma
• Soft Tissue Sarcoma
• Uterine Leiomyosarcoma

Drugs mentioned

• AZD0530 (saracatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Fibrosarcoma, Adult Leiomyosarcoma | Phase 2 | Status: COMPLETED | Results posted: 2015-07-30